Analysts Set Teleflex Incorporated (NYSE:TFX) Price Target at $144.00

Shares of Teleflex Incorporated (NYSE:TFX) have earned an average rating of “Hold” from the nine analysts that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month target price among brokers that have covered the stock in the last year is $144.00.

Several brokerages have commented on TFX. Bank of America raised shares of Teleflex from an “underperform” rating to a “neutral” rating and set a $135.00 price target for the company in a report on Monday, April 13th. Wells Fargo & Company increased their price target on shares of Teleflex from $130.00 to $138.00 and gave the company an “equal weight” rating in a research report on Friday, May 8th. Weiss Ratings reissued a “sell (d)” rating on shares of Teleflex in a research note on Friday, March 27th. Raymond James Financial reissued an “outperform” rating and issued a $150.00 price target on shares of Teleflex in a research note on Friday, May 8th. Finally, Royal Bank Of Canada upgraded shares of Teleflex from a “sector perform” rating to an “outperform” rating and boosted their price objective for the company from $135.00 to $155.00 in a research report on Friday, May 8th.

Teleflex Trading Down 1.7%

Shares of TFX stock opened at $129.90 on Wednesday. The company has a 50 day moving average of $127.08 and a 200-day moving average of $118.04. The firm has a market cap of $5.75 billion, a P/E ratio of -5.70, a PEG ratio of 0.98 and a beta of 0.82. Teleflex has a 12-month low of $100.18 and a 12-month high of $139.67. The company has a quick ratio of 2.03, a current ratio of 2.55 and a debt-to-equity ratio of 0.82.

Teleflex (NYSE:TFX) last released its quarterly earnings data on Thursday, May 7th. The medical technology company reported $1.39 EPS for the quarter, topping the consensus estimate of $1.21 by $0.18. The company had revenue of $548.30 million during the quarter, compared to the consensus estimate of $536.91 million. Teleflex had a negative net margin of 35.88% and a positive return on equity of 13.29%. Teleflex’s revenue for the quarter was up 32.3% on a year-over-year basis. During the same period last year, the firm earned $1.44 EPS. Teleflex has set its FY 2026 guidance at 6.250-6.550 EPS. Sell-side analysts anticipate that Teleflex will post 6.7 earnings per share for the current year.

Teleflex Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 30th. Shareholders of record on Monday, May 25th will be given a $0.34 dividend. The ex-dividend date is Friday, May 22nd. This represents a $1.36 dividend on an annualized basis and a dividend yield of 1.0%. Teleflex’s payout ratio is presently -5.96%.

Hedge Funds Weigh In On Teleflex

Hedge funds and other institutional investors have recently modified their holdings of the stock. Ruffer LLP bought a new position in Teleflex during the fourth quarter valued at approximately $5,154,000. Waterfront Wealth Inc. bought a new position in Teleflex during the fourth quarter valued at approximately $2,050,000. Eos Management L.P. bought a new position in Teleflex in the fourth quarter worth approximately $3,763,000. Capital International Investors bought a new position in Teleflex in the third quarter worth approximately $44,851,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH raised its position in Teleflex by 227.5% in the fourth quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 27,822 shares of the medical technology company’s stock worth $3,395,000 after acquiring an additional 19,327 shares during the period. Hedge funds and other institutional investors own 95.62% of the company’s stock.

Teleflex Company Profile

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.